Company Filing History:
7 out of 417 
1 out of 832,843 Years Active: 2011-2017
Title: Takatoshi Kanayama: Innovator in Urological Therapeutics
Introduction
Takatoshi Kanayama is a prominent inventor based in Tokyo, Japan, known for his significant contributions to the field of urological therapeutics. With a total of eight patents to his name, Kanayama has focused on developing compounds that target specific receptors to address various medical conditions.
Latest Patents
One of Kanayama's latest patents involves an indole compound designed to serve as a MT and/or MT receptor agonist. The problem addressed by this invention is the need for a compound that can effectively act as a therapeutic agent for urinary incontinence, particularly stress urinary incontinence and mixed urinary incontinence. The solution presented by Kanayama and his team confirms that indole compounds possess the necessary activity, leading to the development of a compound represented by a specific formula that exhibits agonistic activity while minimizing central nervous system migration.
Another notable patent is for an indole carboxamide derivative, which relates to compounds that are MT1 and/or MT2 receptor agonists. These compounds are useful for treating and preventing urological diseases, showcasing Kanayama's commitment to advancing medical science in this area.
Career Highlights
Throughout his career, Kanayama has worked with notable companies, including Astellas Pharma GmbH, where he has contributed to research and development efforts aimed at improving patient outcomes in urology. His work has been instrumental in bridging the gap between innovative research and practical therapeutic applications.
Collaborations
Kanayama has collaborated with esteemed colleagues such as Tatsuhisa Takahashi and Takahiro Ishii, further enhancing the impact of his research through teamwork and shared expertise.
Conclusion
Takatoshi Kanayama's innovative work in the field of urological therapeutics highlights his dedication to improving healthcare solutions. His patents reflect a deep understanding of receptor biology and a commitment to addressing significant medical challenges.